Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPRISA 012C
PACTR202112683307570Phase 2Recruiting
- Sponsor
- CAPRISA
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of CAP256V2LS and VRC07-523LS in human immunodeficiency virus infection (HIV) (3 arms), sponsored by CAPRISA. Primary endpoints: Grade 3 or higher solicited reactogenicity events and Grade 3 or higher related unsolicited adverse events. Started Nov 2022; status: recruiting.
02
Drugs
CAP256V2LSVRC07-523LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202112683307570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202112683307570.